EMvision Research Notes, page-2535

Well said. The trading action since the Keysight news "pop" to $2.73 reeks of a very stale overhang and looking at broker data since April shows the biggest seller by far has been Morgans. Until they're done the stock price is not going up. See it as a great opportunity to be buying a quality med tech company at a big discount to the price that Keysight invested $15M. The stock is caught in the well known Valley of Death period but the beauty of this one is they don't need to raise capital again for a long time so killer dilution in the Valley of Death is not applicable here. Management have been exemplary which is very rare in the small cap space. I have added another 100,000 sub $2 during May for which I am very happy. I maintain a strong buy sentiment if holding for two years plus from here.